Entera Bio Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-11.4M | $-9.5M | $-8.9M | $-13.1M | $-12.2M | $-11.2M | $-10.8M | $-10.3M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $30.0K | $46.0K | $56.0K | $64.0K | $53.0K | $63.0K | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.8M | $2.6M | $1.7M | $2.2M | $1.9M | $901.0K | $1.9M | $1.1K |
| Net Cash from Operating Activities | $-7.4M | $-6.8M | $-7.3M | $-12.5M | $-9.1M | $-10.6M | $-8.9M | $-9.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $107.0K | $3.0K | $17.0K | $47.0K | $17.0K | $53.0K | $40.0K | $68.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-107.0K | $-3.0K | $-17.0K | $-102.0K | $-17.0K | $-53.0K | $3.9M | $-4.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $13.7M | $4.5M | $6.0M | $13.0K | $25.4M | $4.1M | $12.7M | $9.6M |
| Net Change in Cash | $6.2M | $-2.3M | $-1.3M | $-12.6M | $16.3M | $-6.6M | $7.7M | $-4.2M |
| Free Cash Flow | $-7.5M | $-6.8M | $-7.3M | $-12.5M | $-9.1M | $-10.6M | $-9.0M | $-9.9M |